Day 1 – 8 July 2013

• The global value chain for TB diagnostics (by M Pai) [Slides]
• Data to scale-up: building the evidence base for new Dx (by M Kimerling) [Slides]
• Scale-up of Xpert MTB/RIF: SA roll out (by L Berrie & S Molapo) [Slides]
• Replacing suboptimal with WHO-endorsed tests in India (by M Pai & M Kaur) [Slides]
• Beyond Xpert: fast-followers and NAAT pipeline (by D Boyle) [Slides]
• POC testing – definitions, TPPs and barriers (by M Pai) [Slides]

Day 2 – 9 July 2013

• Market-based approaches in TB diagnostics (by J Ginnard) [Slides]
• What is the market for TB diagnostics? (by P Chedore & S Kik) [Not available]
• Reference standards: Microscopy studies (by L Davis) [Slides]
• Reference standards: Molecular assays (by P Nabeta) [Slides]
• Reference standards: IGRAs (by D Menzies) [Slides]
• Reference standards: Pediatric TB (by A Ahmed) [Slides]
• Reference standards: Extrapulmonary TB (by G Fox) [Slides]
• Statistical approaches for dealing with imperfect reference standards (by N Dendukuri) [Slides]
• Importance of reproducibility: case study of IGRAs (by N Banaei) [Slides]
• Incremental value of new diagnostics (by M Pai) [Slides]
• Impact of test results on diagnostic thinking (by M Pai) [Slides]
• Impact on patient outcomes: diagnostic RCTs in TB (by L Davis) [Slides]

Day 3 – 10 July 2013

• Measuring clinical impact without randomization: methodological issues (by L Davis) [Slides]
• Maximizing the impact of smear microscopy (by L Davis) [Slides]
• Qualitative research on TB diagnostics (by N Engel) [Slides]
• Xpert MTB/RIF: challenges in low incidence settings (by C Denkinger) [Not available]
• Xpert MTB/RIF in high incidence settings: XTEND study (by V Chihota) [Not available]
• Where to place diagnostics for maximum impact? (by K Palamountain) [Not available]
• Are microscopy centers ready for molecular tests? (by C Denkinger) [Slides]

Day 4 – 11 July 2013

• Systematic reviews of diagnostic accuracy (by K Steingart) [Slides]
• SR: case study: Xpert for EPTB (by C Denkinger) [Not available]
• SR: case study: Predictive value of IGRAs (by S Kik) [Slides]
• Guideline development in TB diagnostics (by K Steingart) [Slides]
• Prequalification of diagnostics, quality assurance and procurement (by A Sands) [Slides]
• Mathematical modeling: an introduction (by D Dowdy) [Slides]

Day 5 – 12 July 2013

• Modeling of TB diagnostics: evaluating new tools (by D Dowdy) [Slides]
• Modeling of TB diagnostics: evaluating the diagnostic process (by D Dowdy) [Slides]
• Introduction to cost-effectiveness analysis (by D Dowdy) [Slides]
• Cost-effectiveness case study: Triage testing for TB (by A van’t Hoog) [Not available]
• Cost-effectiveness case study: Diagnostics for HIV-associated TB (by D Dowdy) [Slides]
• “User-friendly” modeling: introduction, pros and cons (by D Dowdy) [Slides]
• Modeling and cost-effectiveness: a synthesis (by D Dowdy) [Slides]